Calithera Biosciences, Inc. (NASDAQ:CALA) was up 7.5% on Friday . The company traded as high as $17.40 and last traded at $17.25. Approximately 887,828 shares changed hands during trading, an increase of 62% from the average daily volume of 547,649 shares. The stock had previously closed at $16.05.

A number of equities research analysts recently weighed in on CALA shares. Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective on the stock in a research report on Tuesday, July 11th. BidaskClub downgraded Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. William Blair started coverage on Calithera Biosciences in a research report on Thursday. They set an “outperform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective (up previously from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Calithera Biosciences presently has a consensus rating of “Buy” and an average target price of $15.50.

The firm’s 50 day moving average price is $15.66 and its 200 day moving average price is $14.35. The company’s market cap is $611.96 million.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.14. The company had revenue of $7.26 million for the quarter, compared to analyst estimates of $4.80 million. On average, analysts expect that Calithera Biosciences, Inc. will post ($0.81) EPS for the current year.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Keith Orford sold 2,120 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $18.31, for a total value of $38,817.20. The disclosure for this sale can be found here. Insiders own 16.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Calithera Biosciences by 278.2% during the 1st quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock worth $16,888,000 after acquiring an additional 1,075,592 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Calithera Biosciences by 729.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 133,981 shares of the biotechnology company’s stock worth $1,547,000 after acquiring an additional 117,832 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Calithera Biosciences during the 1st quarter worth about $47,550,000. Morgan Stanley boosted its position in shares of Calithera Biosciences by 1,053.6% during the 1st quarter. Morgan Stanley now owns 98,161 shares of the biotechnology company’s stock worth $1,133,000 after acquiring an additional 89,652 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Calithera Biosciences during the 1st quarter worth about $1,152,000. 71.88% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/calithera-biosciences-inc-cala-trading-up-7-5.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.